What is the mechanism by which the aids virus causes deficiency of immune system of the infected person?

Answer

Hint: AIDS stands for Acquired immune deficiency syndrome. It is a syndrome in which the body loses its ability to fight infections.

Complete Answer:

Note: Immune system is a complex system which provides protection to the body against infection. It is a system of many cells, and proteins that work together to defend the body. The immune system also has memory cells which keep a record of every microbe that entered the body so that it can recognise and destroy that particular microbe when it enters the body again.

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science. 1983;220:868–871. [PubMed] [Google Scholar]

2. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre AIDS. Science. 1984;244:497–500. [PubMed] [Google Scholar]

3. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Shiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984;225:840–842. [PubMed] [Google Scholar]

4. Levy JA. Pathogenesis of HIV infection. Microbiol Rev. 1993;57:183–289. [PMC free article] [PubMed] [Google Scholar]

5. Cameron DW, Simonsen JN, D’Costa LJ, Ronald AR, Maitha GM, Gakinya MN, et al. Female to male transmission of human immunodeficiency virus type 1: Risk factors for seroconversion in men. Lancet. 1989;ii:403–407. [PubMed] [Google Scholar]

6. Padian NS, Shiboski SC, Jewell NP. Female to male transmission of Human Immunodeficiency Virus. JAMA. 1991;266:1664–1667. [PubMed] [Google Scholar]

7. Minkoff H, Nanda D, Menez R, Fikrig S. Pregnancies resulting in infants with Acquired Immunodeficiency Syndrome or AIDS Related Complex. Obst Gynecol. 1987;69:285–287. [PubMed] [Google Scholar]

8. Minkoff H, Nanda D, Menez R, Fikrig S. Pregnancies resulting in infants with Acquired Immunodeficiency Syndrome or AIDS-related complex: follow up of mothers, children, and subsequently born siblings. Obst Gynecol. 1987;69:288–291. [PubMed] [Google Scholar]

9. Cloyd MW, Moore BE. Spectrum of biological properties of Human Immunodeficiency virus (HIV-1) isolates. Virology. 1990;174:103–116. [PubMed] [Google Scholar]

10. CDC Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. Morbid Mortal Wkly Rep. 1986;35:334–339. [PubMed] [Google Scholar]

11. CDC Revised classification system for HIV infection and expanded surveillance of definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep. 1993;41:17. [PubMed] [Google Scholar]

12. Rutherford GW, Lifson AR, Hessol NA, Darrow WW, O’Malley PM, Buchbinder SP, et al. Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ. 1990;301:1183–1188. [PMC free article] [PubMed] [Google Scholar]

13. Detels R, Liu Z, Hennessy K, Kan J, Visscher BR, Taylor JM, et al. Resistance to HIV-1 infection. Multicenter AIDS cohort study. J AIDS. 1994;7:1263–1269. [PubMed] [Google Scholar]

14. Paxton WA, Martin SR, Tse D, O’Brien TR, Skurnick J, Vandevanter NL, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med. 1996;2:412–417. [PubMed] [Google Scholar]

15. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med. 1995;1:59–64. [PubMed] [Google Scholar]

16. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763–767. [PubMed] [Google Scholar]

17. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667–673. [PubMed] [Google Scholar]

18. Al-Jabri AA. How Does HIV-1 Infect a Susceptible Human Cell? Current thinking! Sultan Qaboos Univ J Sci Res Med Sci. 2003;5:31–44. [PMC free article] [PubMed] [Google Scholar]

19. Bowers M. Chemokines and HIV. BETA. 1997;3:22–27. [PubMed] [Google Scholar]

20. Feng Y, Border CC, Kennedy PA, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–876. [PubMed] [Google Scholar]

21. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661–666. [PubMed] [Google Scholar]

22. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell tropic isolates: definition of critical amino acids involved in cell tropism. J Virol. 1992;66:6547–6554. [PMC free article] [PubMed] [Google Scholar]

23. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier M, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996;382:833–835. [PubMed] [Google Scholar]

24. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;82:829–833. [PubMed] [Google Scholar]

25. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T Cells. Science. 1995;270:1811–1815. [PubMed] [Google Scholar]

26. Cornelissen M, Mulder-Kampinga G, Veenstra J, Zorgdrager F, Kuiken C, Hartman S, et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol. 1995;69:1810–1818. [PMC free article] [PubMed] [Google Scholar]

27. Schuitemaker H, Koot M, Kootstra NA, Derksen M, de Goede REY, Van Steenwijk P, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T- cell-tropic virus populations. J Virol. 1992;66:1354–1360. [PMC free article] [PubMed] [Google Scholar]

28. Koot M, Keet IPM, Vos AHV, DeGoede REY, Roos MTL, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681–688. [PubMed] [Google Scholar]

29. Arenzana-Seisdedos F, Virelizier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B, et al. HIV blocked by chemokine antagonist. Nature. 1996;383:400. [PubMed] [Google Scholar]

30. Moore JP. Coreceptors: Implications for HIV Pathogenesis and Therapy. Science. 1997;276:51–52. [PubMed] [Google Scholar]

31. Roques PA, Gras G, Parnet-Mathieu F, Mabondzo AM, Dollfus C, Narwa R, et al. Clearance of HIV infection in 12 perinatally infected children: clinical, virological and immunological data. AIDS. 1995;9:F19–F26. [PubMed] [Google Scholar]

32. Joshi VV, Oleske JM, Minnefor AB, Singh R, Bokharit T, Rapkin RH. Pathology of suspected acquired immune deficiency syndrome in children: a study of eight cases. Paediatr Pathol. 1984;2:71–87. [PubMed] [Google Scholar]

33. Just J, Louie L, Abramst E, Nicholast SW, Warat D, Steins Z, et al. Genetic risk factors for perinatally acquired HIV-1 infection. Paediatr Perinat Epidem. 1992;6:215–224. [PubMed] [Google Scholar]

34. Baur A, Schwharz N, Ellinger S, Ellinger S, Korn K, Harrer T, et al. Continuous clearance of HIV in a vertically infected child. Lancet. 1989;ii:1045. [PubMed] [Google Scholar]

35. Baur AS, Sawai ET, Dazin P, Fantl WJ, Cheng MC, Peterlin BM. HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localisation. Immunity. 1994;1:373–384. [PubMed] [Google Scholar]

36. Bryson Y, Chen ISI. HIV clearance in an infant? Nature. 1995;375:637–638. [PubMed] [Google Scholar]

37. Bryson YJ, Pang S, Wei LS, Dickover R, Diagne A, Chen ISI. Clearance of HIV infection in a perinatally infected infant. N Engl J Med. 1995;332:833–838. [PubMed] [Google Scholar]

38. Frenkel LM, Nichols JE, Wagner LE, Haase AT, Roberts NJ., Jr Loss of HIV-1 viremia with persistent specific immunity in a women and her child. J Cellular Biochem. 1995;21:234. [Google Scholar]

39. Perrin LH, Zubler R, Hirschel B, Martin JL, Salomon D, Saurat JH, et al. Reversal of positive serology for human immunodeficiency virus (HIV). A propose of 2 case reports. Schweiz Med Wochenschr. 1988;118:1641–1644. [PubMed] [Google Scholar]

40. Taylor R. Quiet clues to HIV-1 immunity: Do some people resist infection? J NIH Res. 1994;6:29–31. [Google Scholar]

41. Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, Hargrove J, et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med. 2006;3:e262. [PMC free article] [PubMed] [Google Scholar]

42. de Vincenzi I, Mertens T. Male circumcision: a role in HIV prevention? AIDS. 1994;8:153–160. [PubMed] [Google Scholar]

43. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298. [PMC free article] [PubMed] [Google Scholar]

44. Lifson AR, Hessol NA, Buchbinder SP, O’Malley PM, Barnhart L, Segal M, et al. Serum Beta-2-Microglobulin and prediction of progression to AIDS in HIV infection. Lancet. 1992;339:1436–1440. [PubMed] [Google Scholar]

45. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection. Cell. 1996;86:367–377. [PubMed] [Google Scholar]

46. Travers K, Mboup S, Marlink R, Gueye-Ndiaye A, Siby T, Thior I, et al. Natural protection against HIV-1 infection provided by HIV-2. Science. 1995;268:1612–1615. [PubMed] [Google Scholar]

47. Westby M, Manca F, Dalgleish AG. The role of host immune responses in determining the outcome of HIV infection. Immunol Today. 1996;17:120–126. [PubMed] [Google Scholar]

48. Lemp GF, Hirozawa AM, Cohen JB, Derish PA, McKinney KC, Hernandez SR. Survival for women and men with AIDS. J Infect Dis. 1992;166:74–79. [PubMed] [Google Scholar]

49. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. “Genetic Restricion of HIV-1 Infection and Progression to AIDS by a deletion Allele of the CKR-5 Structural gene” Science. 1996;273:1856–1862. [PubMed] [Google Scholar]

50. Ahmed N, Venkatesan S. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science. 1988;241:1481–1485. [PubMed] [Google Scholar]

51. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991;65:651–662. [PubMed] [Google Scholar]

52. Fernandez CE, Desco M, Montes MG, Natividad L, Gonzalez B, Zabay JM. Immunological and serological markers predictive of progression to AIDS in a cohort of HIV infected drug users. AIDS. 1990;4:987–994. [PubMed] [Google Scholar]

53. Gao Y, Qing L, Zhang LQ, Safrit JT, Ho DD. Virological and immunological characterization of long-term survivors of HIV-1 infection. N Eng J Med. 1994;332:201–208. [Google Scholar]

54. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJG, Simmonds P, et al. HLA haplotype A1, B8, DR3 as a risk factors for HIV related disease. Lancet. 1988;i:1185–1188. [PubMed] [Google Scholar]

55. Al-Jabri AA. HLA and in vitro susceptibility to HIV infection. Mol Immunol. 2002;38:959–967. [PubMed] [Google Scholar]

56. Roe DL, Lewis RE, Cruse JM. Association of HLA-DQ and –DR alleles with protection from or infection with HIV-1. Exp Mol Pathol. 2000;68:21–28. [PubMed] [Google Scholar]

57. Al-Jabri AA, Bottazo GF, Mccloskey D, Oxford JS. Evidence for Resistance Among PBMCS from Healthy Bangladeshis to Infection by Certain Isolates of HIV-1 & 2. Abstr P5/1, First European Meeting of Virology; Wurzburg, Germany. September 1995; pp. 10–13. [Google Scholar]

58. Al-Jabri AA, Mccloskey D, Addawee M, Bottazzo FG, Sachs J, Oxford JS. In Vitro Correlation Between Human Leukocyte Antigen Class I and II Phenotype and HIV Infectivity of Activated Peripheral Blood Mononuclear Cell Cultures. AIDS. 1998;12:217–8. [PubMed] [Google Scholar]

59. Al-Jabri AA, Wigg MD, Oxford JS. Initial in vitro screening of drug candidates for their potential antiviral activities. In: Kangro H, Mahy B, editors. Virology Methods Manual. London: Academic Press; 1996. pp. 293–308. [Google Scholar]

60. Cameron PU, Cobain TJ, Zhang WJ, Kay PH, Dawkins RL. Influence of C4 null genes on infection with human immunodeficiency virus. BMJ. 1988;296:1627–1628. [PMC free article] [PubMed] [Google Scholar]

61. Cameron PU, Mallal SA, French MAH, Dawkins RL. Major histocompatibility complex genes influence the outcome of HIV infection, Ancestral haplotypes with C4 null alleles explain diverse HLA associations. Hum Immunol. 1990;29:282–295. [PubMed] [Google Scholar]

62. Fabio G, Scorza R, Lazzarin A, Marchini M, Zarantonello M, D’Arminio A, et al. HLA associated susceptibility to HIV-1 infection. Clin Exp Immunol. 1992;87:20–23. [PMC free article] [PubMed] [Google Scholar]

63. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;283:1748–1752. [PubMed] [Google Scholar]

64. de Sorrentino AH, Marinic K, Motta P, Sorrentino A, Lopez R, Illiovich E. HLA class I alleles associated with susceptibility or resistance to human immunodeficiency virus type 1 infection among a population in Chac province, Argentina. J Infect Dis. 2000;182:1523–1526. [PubMed] [Google Scholar]

65. MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S, et al. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis. 2001;183:503–506. [PubMed] [Google Scholar]

66. Mann D, Carrington M, Kroner BL. The human major histocompatibility complex and HIV-1 pathogenesis. AIDS. 1994;8:S53–S60. [Google Scholar]

67. McNeil AJ, Yap PL, Gore SM, Brettle RP, McColl M, Wyld R, et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Q J Med. 1996;89:177–185. [PubMed] [Google Scholar]

68. Habeshaw JA, Wilson SE, Hounsell EF, Oxford JS. How HIV-1 lentivirus causes immune deficiency disease. Med Hypoth. 1999;52:59–67. [PubMed] [Google Scholar]

69. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, Zeleniuch-Jacquotte A, et al. HLA-B35 is associated with accelerated progression to AIDS. J IDS. 1991;5:37–45. [PubMed] [Google Scholar]

70. Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, Costagliola D. Progression to AIDS in French haemophiliacs: association with HLA-B35. AIDS. 1993;7:497–500. [PubMed] [Google Scholar]

71. Scorza SR, Fabio G, Lazzarin A, Eisera N, Foppa Ulberti C, Moroni M, et al. HLA associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV infected intravenous drug addicts. Hum Immunol. 1988;22:73–79. [PubMed] [Google Scholar]

72. Scorza SR, Fabio G, Lazzarin A, Eisera NB, Moroni M, Zanussi C. HLA associated susceptibility to Acquired Immunodeficiency Syndrome in Italian patients with Human Immunodeficiency Virus infection. Lancet. 1986;ii:1187–1189. [PubMed] [Google Scholar]

73. Palumbo Paul, Skurnick Joan, Rohowsky-Kochan Christine, Louria Donald. Natural resistance to HIV: Is the evidence good enough to design an effective vaccine. AIDS Science. 2002;2:11. [Google Scholar]

74. Altfeld MA, Livingston B, Reshamwala N, Nguyen PT, Addo MM, Shea A, et al. Identification of Novel HLAA2-Restricted Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Epitopes Predicted by the HLA-A2 Supertype Peptide-Binding Motif. J Virol. 2001;75:1301–1311. [PMC free article] [PubMed] [Google Scholar]

75. Louie LG, Newman B, King M-C. Influence of host genotype on progression to AIDS among HIV infected men. AIDS. 1991;4:814–818. [PubMed] [Google Scholar]

76. Spear GT. Interaction of non-antibody factors with HIV in plasma. AIDS. 1993;7:1149–1157. [PubMed] [Google Scholar]

77. Spear GT, Sullivan BL, Landay AL, Lint TF. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol. 1990;64:5869–5873. [PMC free article] [PubMed] [Google Scholar]

78. Moir S, Malaspina A, Li Y, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med. 2000;192:637–646. [PMC free article] [PubMed] [Google Scholar]

79. Sullivan BL, Knopoff EJ, Saifuddin M, et al. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol. 1996;157:1791–1798. [PubMed] [Google Scholar]

80. Sullivan BL, Takefman DM, Spear GT. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology. 1998;248:173–181. [PubMed] [Google Scholar]

81. Kacani L, Prodinger WM, Sprinzl GM, et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol. 2000;74:7997–8002. [PMC free article] [PubMed] [Google Scholar]

82. Takefman DM, Sullivan BL, Sha BE, Spear GT. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology. 1998;246:370–378. [PubMed] [Google Scholar]

83. Spear GT, Hart M, Olinger GG, Hashemi FB, Saifuddin M. The role of the complement system in virus infections. Curr Top Microbiol Immunol. 2001;260:229–245. [PubMed] [Google Scholar]

84. Bogdan C. The function of type I interferons in antimicrobial immunity. Curr Opin Immunol. 2000;12:419–424. [PubMed] [Google Scholar]

85. Cousens LP, Peterson R, Hsu S, Dorner A, Altman JD, Ahmed R, et al. Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J Exp Med. 1999;189:1315–1328. [PMC free article] [PubMed] [Google Scholar]

86. Krown SE. Interferon-alpha: evolving therapy for AIDS-associated Kaposi’s sarcoma. J Interferon Cytokine Res. 1998;18:209–214. [PubMed] [Google Scholar]

87. DeStefano E, Friedman RM, Friedman-Kien AE, et al. Acid-labile human leukocyte interferon in homosexual men with Kaposi’s sarcomaand lymphadenopathy. J Infect Dis. 1982;146:451–459. [PubMed] [Google Scholar]

88. Ferbas J, Navratil J, Logar A, Rinaldo C. Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV infection. Clin Diagn Lab Immunol. 1995;2:138–142. [PMC free article] [PubMed] [Google Scholar]

89. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood. 2001;98:906–912. [PubMed] [Google Scholar]

90. Siegal FP, Lopez C, Fitzgerald PA, Shah K, Baron P, Leiderman IZ, et al. Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. J Clin Invest. 1986;78:115–123. [PMC free article] [PubMed] [Google Scholar]

91. Smith SM. HIV vaccine development in the nonhuman primate model of AIDS. J Biomed Sci. 2002;9:100–11. [PubMed] [Google Scholar]

92. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996;271:324–328. [PubMed] [Google Scholar]

Page 2

List of some of the factors that can affect AIDS progression